These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 37271529)

  • 61. [New therapeutic directions on hemophilia].
    Suzuki T
    Rinsho Ketsueki; 2019; 60(9):1275-1282. PubMed ID: 31597853
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Multicenter retrospective study on the utilization of FEIBA in France in patients with factor VIII and factor IX inhibitors. French FEIBA Study Group. Factor Eight Bypassing Activity.
    Negrier C; Goudemand J; Sultan Y; Bertrand M; Rothschild C; Lauroua P
    Thromb Haemost; 1997 Jun; 77(6):1113-9. PubMed ID: 9241742
    [TBL] [Abstract][Full Text] [Related]  

  • 63. A history of prophylaxis in haemophilia.
    Moreno MM; Cuesta-Barriuso R
    Blood Coagul Fibrinolysis; 2019 Mar; 30(2):55-57. PubMed ID: 30507712
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Current challenges in the management of hemophilia.
    Bauer KA
    Am J Manag Care; 2015 Mar; 21(6 Suppl):S112-22. PubMed ID: 26168206
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Current status of hemophilia patients and recombinant coagulation factor concentrates in Japan.
    Fukutake K
    Semin Thromb Hemost; 2000; 26(1):29-32. PubMed ID: 10805278
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Progress in the treatment of bleeding disorders.
    Bergman GE
    Thromb Res; 2011 Jan; 127 Suppl 1():S3-5. PubMed ID: 21035836
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Recent improvements in the clinical treatment of coagulation factor inhibitors.
    Franchini M; Lippi G
    Semin Thromb Hemost; 2009 Nov; 35(8):806-13. PubMed ID: 20169517
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Molecular approaches for improved clotting factors for hemophilia.
    Kaufman RJ; Powell JS
    Blood; 2013 Nov; 122(22):3568-74. PubMed ID: 24065241
    [TBL] [Abstract][Full Text] [Related]  

  • 69. New products for the treatment of haemophilia.
    Laffan M
    Br J Haematol; 2016 Jan; 172(1):23-31. PubMed ID: 26456702
    [TBL] [Abstract][Full Text] [Related]  

  • 70. [Hemostatic management of hemophilia].
    Tokugawa T
    Rinsho Ketsueki; 2022; 63(9):1212-1222. PubMed ID: 36198547
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Hemophilia. Strategies for the treatment of inhibitor patients.
    Ingerslev J
    Haematologica; 2000 Oct; 85(10 Suppl):15-20. PubMed ID: 11187863
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Effects of replacement therapies with clotting factors in patients with hemophilia: A systematic review and meta-analysis.
    Delgado-Flores CJ; García-Gomero D; Salvador-Salvador S; Montes-Alvis J; Herrera-Cunti C; Taype-Rondan A
    PLoS One; 2022; 17(1):e0262273. PubMed ID: 35030189
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Immune Responses to Plasma-Derived Versus Recombinant FVIII Products.
    Peyvandi F; Miri S; Garagiola I
    Front Immunol; 2020; 11():591878. PubMed ID: 33552050
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Recombinant factor VIIa concentrate versus plasma-derived concentrates for treating acute bleeding episodes in people with haemophilia and inhibitors.
    Matino D; Makris M; Dwan K; D'Amico R; Iorio A
    Cochrane Database Syst Rev; 2015 Dec; 2015(12):CD004449. PubMed ID: 26677005
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Health status and quality of life of elderly persons with severe hemophilia born before the advent of modern replacement therapy.
    Siboni SM; Mannucci PM; Gringeri A; Franchini M; Tagliaferri A; Ferretti M; Tradati FC; Santagostino E; von Mackensen S;
    J Thromb Haemost; 2009 May; 7(5):780-6. PubMed ID: 19220727
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Hemostasis: a practical review of conservative and operative care.
    Shopnick RI; Brettler DB
    Clin Orthop Relat Res; 1996 Jul; (328):34-8. PubMed ID: 8653974
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Recombinant factor VIII Fc fusion protein for the prevention and treatment of bleeding in children with severe hemophilia A.
    Young G; Mahlangu J; Kulkarni R; Nolan B; Liesner R; Pasi J; Barnes C; Neelakantan S; Gambino G; Cristiano LM; Pierce GF; Allen G
    J Thromb Haemost; 2015 Jun; 13(6):967-77. PubMed ID: 25912075
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Prevention of bleeding in hemophilia patients with high-titer inhibitors.
    Leissinger CA; Konkle BA; Antunes SV
    Expert Rev Hematol; 2015 Jun; 8(3):375-82. PubMed ID: 25937074
    [TBL] [Abstract][Full Text] [Related]  

  • 79. A Budget Impact Model of Hemophilia Bypassing Agent Prophylaxis Relative to Recombinant Factor VIIa On-Demand.
    Mehta DA; Oladapo AO; Epstein JD; Novack AR; Neufeld EJ; Hay JW
    J Manag Care Spec Pharm; 2016 Feb; 22(2):149-57. PubMed ID: 27015254
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Half-life extended factor VIII for the treatment of hemophilia A.
    Tiede A
    J Thromb Haemost; 2015 Jun; 13 Suppl 1():S176-9. PubMed ID: 26149020
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.